---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-066641"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:48:30.023592+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q2 revenue $18.8M (+36% YoY); GAAP EPS loss $(0.22); guides FY rev >=$100M

## Summary
- Revenue $18.8M (+36% YoY); gross profit $11.7M (+50%); gross margin 62%.
- GAAP net loss $(4.0M) ($(0.22)/share); non-GAAP net income $0.3M ($0.02/diluted).
- Adjusted EBITDA $0.5M vs $(0.8M) prior year; FY2024 guidance reaffirmed: rev >=$100M, Adj EBITDA >=$11M.
- CEO cites ~$6M DAAP program delayed from Q2; without delay would have exceeded consensus.
- KPIs: avg rev per top 20 pharma $2.7M (up from $1.8M); net revenue retention 124% (vs 89%).

## SEC filing metadata
- accession: 0001213900-24-066641
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390024066641/0001213900-24-066641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390024066641/ea0210870-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-066641
- JSON: https://secwatch.observer/filing/0001213900-24-066641.json
- Plain text: https://secwatch.observer/filing/0001213900-24-066641.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.